• Persistent anxiety: Prolonged feelings of worry or nervousness.
• Depression: Feelings of sadness, hopelessness, or loss of interest in activities.
• Insomnia: Difficulty sleeping or staying asleep.
• Psychotic symptoms: Hallucinations, delusions, or paranoia.
• Flashbacks: Unexpected and spontaneous reliving of experiences while using the drug.

These symptoms can occur within a few days to several weeks after quitting and can last for several weeks or longer. The length and severity of withdrawal can vary depending on the individual and their level of dissociative use.

Here are some steps you can take at home to help manage dissociative withdrawal:

Gradual reduction: Gradually reducing the frequency and amount of dissociative use can help minimize withdrawal symptoms and prevent severe side effects.

Hydration: Drink plenty of water to help replace fluids lost due to excessive dissociative use.

Nutrition: Eat a balanced and nutritious diet to help replenish vitamins and minerals lost due to dissociative use.

Sleep: Get enough rest and sleep to help the body recover from the effects of dissociatives.

Exercise: Engage in physical activity, such as walking or yoga, to help reduce stress and anxiety.

Support: Seek support from friends, family, or a support group to help you through the withdrawal process.

Medications: Over-the-counter pain relievers such as ibuprofen or acetaminophen can help relieve headaches and body aches.

The post Symptoms of dissociative withdrawal appeared first on Mindheal.

Dans cet article, je vais essayer une nouvelle approche : chaque sous-titre fera partie de la réponse à la question du titre. Donc, si un sous-titre vous semble incompréhensible ou inapproprié, souvenez-vous du titre de cet article. Il me semble que c’est quelque chose de nouveau. Assez parlé, c’est parti !

L’amphétamine, en tant que stimulant typique, manifeste ses effets en augmentant les niveaux des neurotransmetteurs dopamine et noradrénaline dans notre cerveau.

Les neurotransmetteurs sont des biocomposés actifs avec lesquels les cellules nerveuses du cerveau « communiquent », transmettent des impulsions et maintiennent notre système nerveux dans toute sa complexité.

La dopamine et la noradrénaline appartiennent au même groupe de neurotransmetteurs – les monoamines. De plus, avec l’adrénaline, elles constituent un sous-groupe appelé catécholamines. De plus, la noradrénaline est un précurseur chimique de l’adrénaline.

Les catécholamines jouent un rôle clé dans l’attention, la motivation et la récompense, c’est pourquoi l’amphétamine peut être utilisée pour traiter des affections telles que le trouble du déficit de l’attention avec hyperactivité (TDAH) et la narcolepsie.

Pénètre dans les neurones

Pour agir, l’amphétamine doit d’abord pénétrer dans le neurone. Après être entrée dans la circulation sanguine via le système digestif, les muqueuses ou directement, l’amphétamine pénètre rapidement dans le cerveau, infiltrant nos neurones.

La structure de l’amphétamine est très similaire à celle des catécholamines. Par conséquent, elle se lie efficacement aux ions sodium et chlore et est facilement transportée dans les cellules nerveuses soit par diffusion simple, soit avec l’aide d’une protéine porteuse DAT (que nous examinerons plus en détail plus tard). C’est là que commence l’aspect le plus intriguant.

Les mécanismes moléculaires précis sous-jacents aux effets de l’amphétamine (ainsi que de nombreuses autres substances) ne sont pas entièrement compris, étant complexes et multiformes ; cependant, plusieurs voies clés ont été identifiées.

La principale chose à savoir est que l’amphétamine élève les niveaux de dopamine et de noradrénaline dans le cerveau, et elle le fait par plusieurs moyens simultanément.

Augmente le niveau de monoamines

L’amphétamine augmente la libération de dopamine et de noradrénaline des cellules nerveuses (neurones). Les cellules nerveuses produisent des neurotransmetteurs, mais ces substances ne deviennent actives que lorsqu’elles entrent dans l’espace entre les neurones, plus précisément, entre des processus spéciaux des neurones à travers lesquels les signaux chimico-électriques sont transmis, connus sous le nom de synapses, et l’espace entre eux est appelé la fente intersynaptique.

L’amphétamine stimule l’activité de protéines appelées transporteurs vésiculaires de monoamines (VMAT, spécifiquement VMAT2), qui sont responsables du transport de ces neurotransmetteurs vers des vésicules pour stockage dans les cellules nerveuses.

Rappelons que l’amphétamine entre dans la synapse d’un neurone car elle est chimiquement similaire aux monoamines. En atteignant l’extrémité de la synapse (terminaison présynaptique), cela prouve à nouveau avantageux pour l’amphétamine. Elle déplace d’autres monoamines associées à VMAT2, ce qui entraîne le pompage des neurotransmetteurs dans l’espace entre les synapses – ce processus est appelé rétrotransport. Cela conduit à une augmentation de la quantité de dopamine et de noradrénaline entre les synapses.

De plus, l’amphétamine est un puissant agoniste (active la fonction) du récepteur associé à l’amine trace 1 (TAAR1). Cela entraîne une augmentation de la concentration de monoamines dans la fente synaptique et contribue à augmenter la liaison aux récepteurs postsynaptiques.

L’effet cumulatif de l’amphétamine via VMAT2 et TAAR1 se traduit par une abondance de noradrénaline et de dopamine dans les synapses. Les signaux associés à ces neurotransmetteurs commencent à entrer activement dans les centres du système nerveux et produisent les effets souhaités.

De plus, l’amphétamine augmente l’activité des récepteurs alpha-2A adrénergiques dans le cerveau, responsables de la libération de noradrénaline, entraînant une augmentation de la vigilance, de l’attention et de l’énergie.

Réduit la recapture des monoamines

Mais ce n’est pas tout, parallèlement, l’amphétamine réduit la recapture de la dopamine et de la noradrénaline. La recapture est une réaction naturelle lorsque la synapse réabsorbe les neurotransmetteurs en elle-même, cessant de signaler à un autre neurone ou à une autre cellule ; cela est nécessaire pour réguler les processus qui se produisent dans le système nerveux.

Par conséquent, si la recapture des médiateurs de signalisation est réduite, ils s’accumuleront dans l’espace entre les synapses et augmenteront l’activité dans les centres de récompense et de motivation du cerveau, comme c’est le cas avec les catécholamines, conduisant à la « montée » ou à l’euphorie associée à l’amphétamine.

Pour réduire la recapture des catécholamines, l’amphétamine se lie aux transporteurs de la dopamine (transporteur actif de dopamine, DAT) et, potentiellement, de la noradrénaline, réduisant ou suspendant leur fonction.

L’amphétamine modifie la structure chimique de DAT (la phosphoryle) et ce dernier est absorbé par le neurone. Le nombre de DAT diminue, ce qui signifie que les fonctions qu’il remplit diminueront également. La dopamine sera moins transférée de la fente intersynaptique à la synapse.

L’amphétamine est connue pour être un faible inhibiteur de la recapture de la dopamine, un inhibiteur modéré de la recapture de la noradrénaline et un très faible inhibiteur de la recapture de la sérotonine. Cet aspect peut provoquer l’effet classique plus stimulant de l’amphétamine que celui euphorique.

Change l’activité des récepteurs et autre chose

Un autre mécanisme par lequel l’amphétamine impacte le cerveau est par des changements dans l’activité de certains récepteurs. L’amphétamine augmente l’activité des récepteurs dopaminergiques D1 et D2, impliqués dans les centres de récompense et de motivation du cerveau, les faisant interagir plus facilement, rapidement et efficacement avec la dopamine, contribuant à l’obtention des effets désirés.

Enfin, il est reconnu que l’amphétamine est un inhibiteur de l’enzyme liée aux mitochondries, la monoamine oxydase (MAO), responsable de la dégradation des neurotransmetteurs en excès. Avec son inhibition, l’excès de monoamines ne sera pas décomposé, et leur concentration dans la fente synaptique augmentera considérablement, entraînant une augmentation de la signalisation. Ce mécanisme est souvent sous-estimé car l’amphétamine est un faible inhibiteur de la MAO, mais il ne doit pas être négligé.

Se manifeste dans différentes parties du cerveau

Nous avons appris les mécanismes par lesquels l’amphétamine exerce ses effets, mais elle a plusieurs effets. De quoi cela dépend-il ? En bref, cela dépend de la partie du cerveau affectée par l’amphétamine.

Ainsi, une motivation accrue et l’euphorie sont causées par une augmentation des niveaux de dopamine dans la voie mésolimbique, un tractus nerveux dans le cerveau qui joue un rôle crucial dans les mécanismes de la mémoire, des émotions, de l’apprentissage et de la régulation neuroendocrinienne et est considéré comme essentiel dans la production de sentiments de plaisir.

De plus, l’activité motrice et en partie l’euphorie en tant qu’effets de l’action de l’amphétamine dépendent de l’augmentation de la concentration de dopamine et de noradrénaline dans le striatum, une structure de notre cerveau qui régule le tonus musculaire, participe aux processus d’encouragement et de renforcement, et joue également un rôle dans la formation du comportement impulsif.

Le profil complet des effets de l’amphétamine est fourni non seulement par la dopamine et la noradrénaline. Le rôle d’autres monoamines et d’autres substances actives a également été noté : sérotonine, histamine, peptides CART, opioïdes endogènes, corticostéroïdes et glutamate. Nous savons que l’amphétamine affecte également toutes ces substances et montre ses effets à travers elles, mais les mécanismes spécifiques et le tableau complet de ce qui se passe ne sont pas encore totalement compris.

The post Comment fonctionne l’amphétamine? appeared first on Mindheal.

The Escalation of the Opioid Crisis

The opioid epidemic has reached alarming heights, with opioid overdose deaths tripling over the past decade. In 2022 alone, the US saw 81,806 opioid-related deaths. This surge has been driven by various waves of opioid misuse, starting with prescription opioids, followed by heroin, synthetic opioids like fentanyl, and most recently, the co-use of stimulants such as methamphetamines and cocaine.

Life Expectancy and Years of Life Lost

The study employed cause-eliminated life tables to estimate the reduction in life expectancy and total YLL due to opioid overdose deaths. The findings are stark: opioid-related deaths in 2022 resulted in an estimated 3.1 million years of life lost, averaging 38 years per death. Nationally, opioid-related mortality reduced life expectancy by 0.67 years in 2022, up from 0.52 years in 2019.

Demographic Disparities

The burden of opioid-related mortality has worsened across all racial and ethnic groups. From 2019 to 2022, life expectancy reductions varied significantly:

• White men: 0.76 years to 0.96 years
• White women: 0.36 years to 0.55 years
• Black men: 0.59 years to 1.1 years
• Black women: 0.27 years to 0.53 years
• Hispanic men: 0.31 years to 0.82 years
• Hispanic women: 0.19 years to 0.31 years
• American Indian/Alaska Native (AI/AN) men: 0.62 years to 1.5 years
• AI/AN women: 0.43 years to 1 year
• Asian men: 0.09 years to 0.2 years
• Asian women: 0.08 years to 0.13 years

These figures indicate a substantial increase in mortality burden, particularly among AI/AN, Black, and Hispanic populations, which now approach or exceed the burden experienced by white Americans.

Polysubstance Use: A Growing Concern

Polysubstance use, especially the co-use of opioids with stimulants like cocaine and methamphetamines, has emerged as a significant factor in opioid-related deaths. In 2022, such combinations were involved in half of all opioid overdose deaths, with variations in predominant drug classes by state and racial/ethnic group.

Geographic Variations

Nearly all states experienced an increase in YLL per capita from 2019 to 2022, with YLL more than doubling in 16 states. West Virginia, Delaware, and Maine saw the highest rates of YLL per capita, while states like Hawaii, Nebraska, and South Dakota reported significantly lower rates.

The COVID-19 Pandemic’s Role

The onset of the COVID-19 pandemic exacerbated the opioid crisis, with disruptions to social, economic, and healthcare systems contributing to the rise in fatal overdoses. The study period coincides with the pandemic years, highlighting the compounded public health challenges.

Implications for Policy and Public Health

Despite significant investments to curb the opioid crisis, opioid overdose mortality has continued to rise. The study underscores the urgent need for transformative policy approaches that address the underlying causes of opioid misuse, enhance access to treatment, and tackle the growing issue of polysubstance use.

Conclusion

The latest findings on the opioid crisis reveal a worsening scenario with significant implications for life expectancy and public health in the US. As the crisis evolves, particularly with the rise in polysubstance use, comprehensive and equitable strategies are crucial to mitigate its impact and save lives. The study calls for renewed and robust efforts to address this ongoing public health emergency.

References

Hébert, A. H., & Hill, A. L. (2024). Impact of opioid overdoses on US life expectancy and years of life lost, by demographic group and stimulant co-involvement: a mortality data analysis from 2019 to 2022. The Lancet Regional Health – Americas, 36, 100813. https://doi.org/10.1016/j.lana.2024.100813

The post US Opioid Crisis: Life Expectancy Drops, Polysubstance Use on the Rise, Study Finds appeared first on Mindheal.

The Study: An Overview

Conducted by researchers from Kaiser Permanente Northern California and the University of California, San Francisco, the study aimed to explore whether prenatal cannabis use is linked to adverse maternal health outcomes during pregnancy. The population-based retrospective cohort study included 316,722 pregnancies in Northern California from January 2011 to December 2019. The researchers evaluated prenatal cannabis use through self-reports and toxicology tests conducted at around 8-10 weeks of gestation.

Key Findings

The study revealed that prenatal cannabis use is associated with several negative maternal health outcomes. Notably, cannabis use during pregnancy was linked to increased risks of:

• Gestational Hypertension: Pregnant individuals who used cannabis had a 17% higher risk of developing gestational hypertension compared to those who did not use cannabis.
• Preeclampsia: The risk of preeclampsia, a severe form of hypertension that can lead to serious complications, was 8% higher among cannabis users.
• Gestational Weight Gain Outside Guidelines: Both insufficient and excessive weight gain during pregnancy were more common among cannabis users. The risk of gaining less than the recommended weight was 5% higher, while the risk of gaining more than the recommended weight was 9% higher.
• Placental Abruption: The study found a 19% higher risk of placental abruption, a condition where the placenta detaches from the uterus prematurely, among those who used cannabis during pregnancy.

Interestingly, the study also found a decreased risk of gestational diabetes among cannabis users, with a risk reduction of 11%. However, the researchers caution that this finding requires further investigation to understand the underlying mechanisms.

Implications and Future Research

Dr. Kelly C. Young-Wolff, the lead author of the study, emphasized the complexity of the relationship between prenatal cannabis use and maternal health. “Our findings suggest that the use of cannabis during pregnancy can lead to several adverse health outcomes for the mother,” said Dr. Young-Wolff. “Given the increasing prevalence of cannabis use among pregnant individuals, it is crucial to continue researching its effects to provide clear guidelines and support for expecting mothers.”

The study’s results highlight the need for further research to explore how different factors, such as the dose, mode, and timing of cannabis use, might influence these health outcomes. Additionally, there is a need to investigate the potential long-term effects on both maternal and fetal health.

Conclusion

As cannabis legalization continues to expand, it is essential for healthcare providers to understand and communicate the potential risks of prenatal cannabis use to their patients. This study provides valuable insights that can inform clinical guidelines and public health policies aimed at ensuring the health and safety of both mothers and their babies.

For expecting mothers considering or currently using cannabis, it is advised to discuss their use with healthcare providers to weigh the potential risks and benefits carefully. As always, making informed decisions in consultation with medical professionals is the best approach to ensuring a healthy pregnancy and positive outcomes for both mother and child.

References

Young-Wolff, K. C., Adams, S. R., Alexeeff, S. E., Zhu, Y., Chojolan, E., Slama, N. E., Does, M. B., Silver, L. D., Ansley, D., Castellanos, C. L., & Avalos, L. A. (2024). Prenatal Cannabis Use and Maternal Pregnancy Outcomes. JAMA Internal Medicine. Published online July 22, 2024. DOI:10.1001/jamainternmed.2024.3270.

The post Cannabis and Pregnancy: New Study Shows Elevated Health Risks for Mothers appeared first on Mindheal.

A Comprehensive Study to Understand Bystander Behavior

A recent study published in the Harm Reduction Journal by Thompson et al. delved deep into the dynamics of bystander responses to opioid overdoses in Connecticut, aiming to identify effective policy options for enhancing the impact of GSLs. This study utilized a systems-level approach, engaging a diverse group of stakeholders through six Group Model Building (GMB) workshops. Participants included medical professionals, community members, first responders, and individuals with lived experience of witnessing overdoses.

Key Findings: The Dynamics of Bystander Behavior

The study’s qualitative system dynamics (SD) model revealed intricate feedback loops and systemic interactions that influence bystander behavior. The model highlighted four key narrative domains:

1. Overdose, Calling 911, and First Responder Burnout: This narrative explored the complex interplay between calling 911 during an overdose and the resulting impact on first responders. Reinforcing feedback loops showed that while calling 911 saves lives, the increased demand on first responders can lead to burnout and stigmatization of individuals with opioid use disorder (OUD), ultimately discouraging future 911 calls.
2. Naloxone Use, Acceptability, and Linking Patients to Services: This narrative underscored the importance of naloxone, a life-saving drug that reverses opioid overdoses. The study found that while increased naloxone use can prevent deaths, its effectiveness is limited if overdose victims are not linked to treatment services, potentially leading to repeated overdoses.
3. Drug Arrests, Belief in Good Samaritan Laws, and Community Trust in Police: The relationship between law enforcement and the community was a critical factor. The fear of arrest and negative interactions with police can deter bystanders from seeking help during overdoses. Building trust and fostering a culture of harm reduction within law enforcement can significantly improve community willingness to call 911.
4. Bystander Naloxone Use, Community Participation in Harm Reduction, and Cultural Change Towards Carrying Naloxone: This narrative highlighted how successful naloxone administration can encourage broader community participation in harm reduction efforts, promoting a cultural shift towards carrying and using naloxone.

High-Leverage Policy Recommendations

Based on the findings, the study identified nine high-impact strategies categorized into four themes:

1. Naloxone Access & Use: Expanding programs like naloxone “leave behind” initiatives and ensuring that EMS, fire, and police departments carry and administer naloxone.
2. Community-Based Harm Reduction Services & Teams: Enhancing connections between overdose victims and addiction treatment services, implementing recovery navigator programs, and providing services at overdose sites.
3. Safer Drug Use: Establishing safe spaces for drug use and developing smartphone applications that alert others in case of an overdose.
4. Education to Reduce Stigma: Training new law enforcement and emergency department staff to reduce stigma and engaging medical trainees to foster a supportive clinical culture.

Conclusion: Towards a Holistic Approach

The study by Thompson et al. underscores the complexity of addressing opioid overdoses and the critical role of systemic, multifaceted approaches. By understanding the dynamics of bystander behavior and the interplay of various social, structural, and policy factors, policymakers can design more effective strategies to reduce opioid-related deaths. Building trust, expanding access to naloxone, and fostering community participation in harm reduction are key steps towards a more resilient and supportive system for individuals with OUD in Connecticut.

For more in-depth insights and detailed policy recommendations, the full study can be accessed here.

The post Improving Opioid Outcomes: Insights from Connecticut’s Good Samaritan Laws appeared first on Mindheal.

The Experiment

The study employed an innovative approach known as precision functional mapping, involving extensive MRI sessions—about 18 per participant. This method enabled researchers to track individual-specific brain changes before, during, and after administering psilocybin (25 mg) and methylphenidate (40 mg), with a follow-up psilocybin dose 6-12 months later.

Key Findings

1. Massive Disruption of Brain Connectivity:
Psilocybin caused a threefold greater disruption in functional connectivity (FC) compared to methylphenidate. The most pronounced effects were observed in the default mode network (DMN), a crucial brain network associated with our sense of self, space, and time.

2. Desynchronization Across Brain Networks:
The disruptions were characterized by brain desynchronization across various spatial scales, reducing correlations within networks and anticorrelations between networks. This desynchronization suggests a breakdown in the typical patterns of brain activity, leading to a state of increased entropy or randomness.

3. Persistent Effects:
Interestingly, the study found that psilocybin-induced changes in FC between the anterior hippocampus and DMN persisted for weeks. This prolonged decrease in connectivity could be linked to the therapeutic effects observed in clinical trials for conditions like depression and anxiety.

4. Subjective Experiences and Brain Changes:
There was a strong correlation between individual differences in FC changes and the subjective psychedelic experience. The intensity of mystical experiences, measured using the Mystical Experience Questionnaire (MEQ30), was closely linked to the degree of brain network desynchronization.

Therapeutic Implications

The findings shed light on the potential mechanisms underlying the therapeutic effects of psychedelics. The persistent decrease in hippocampal-DMN connectivity, for instance, could represent a neuroanatomical correlate of the proplasticity and therapeutic effects of psilocybin. This aligns with previous animal studies showing increased synaptogenesis and neuroplasticity in the cortex and hippocampus following psychedelic exposure.

The Bigger Picture

The research offers a promising glimpse into how psychedelics can be harnessed to treat mental health disorders. By disrupting the brain’s usual patterns of connectivity, psilocybin might “reset” dysfunctional neural circuits associated with depression, anxiety, and other conditions. However, the study also underscores the need for further research, particularly in clinical settings, to fully understand and optimize these effects for therapeutic use.

Conclusion

Dr. Siegel and his team’s groundbreaking work provides valuable insights into the profound and lasting effects of psilocybin on the human brain. As the scientific community continues to unravel the complexities of psychedelic substances, studies like this highlight their potential to revolutionize mental health treatment, offering hope to millions suffering from debilitating conditions.

References:

• Siegel, J. S., et al. (2024). Psilocybin desynchronizes the human brain. Nature. DOI: 10.1038/s41586-024-07624-5

For more in-depth information and access to the full study, visit Nature’s website.

The post How Psilocybin Desynchronizes Human Brain Networks appeared first on Mindheal.

The Study’s Objectives

Cocaine craving, a core symptom of CUD, poses significant challenges in addiction treatment. Traditional methods of cue-exposure therapy have shown varying degrees of success, prompting researchers to explore more immersive and engaging techniques. The study aimed to assess the feasibility of using VR to induce cocaine cravings in users, comparing VR exposure to cocaine-related cues with neutral VR environments.

Methodology

The study involved 11 chronic cocaine users, including crack smokers, snorters, and injectors. Participants underwent three 10-minute tasks in a controlled environment:

1. Neutral VR Exposure: Participants interacted with a virtual apartment featuring neutral objects and environments.
2. Cocaine VR Exposure: The same virtual apartment was transformed with cocaine-related stimuli, including paraphernalia and scenarios mimicking drug use.
3. Relaxation Procedure: A paced-breathing relaxation exercise aimed at reducing any residual craving and discomfort.

The primary outcome was measured using the Cocaine Craving Questionnaire-Brief (CCQ-Brief), while secondary outcomes included changes in emotional states and self-efficacy to cope with cravings.

Key Findings

The study found significant increases in cocaine craving scores during the cocaine VR exposure compared to the neutral VR exposure. This suggests that VR is a potent tool for inducing cravings, potentially more effective than traditional cue-exposure methods. Notably, the relaxation procedure post-exposure helped return craving and emotional states to baseline levels, highlighting its therapeutic potential.

The findings of this study pave the way for innovative treatments in CUD. By providing a controlled, immersive environment, VR can enhance cue-exposure therapy’s effectiveness, making it a promising tool for both research and clinical applications. The ability to tailor VR scenarios to individual needs and monitor real-time reactions offers a personalized approach to addiction therapy.

Future Directions

While this study is a significant step forward, further research is needed to compare the efficacy of VR-based cue-exposure with non-VR methods and explore its long-term benefits in addiction treatment. The integration of VR in therapeutic settings could revolutionize how we approach addiction, providing more engaging, effective, and tailored treatment options for those struggling with CUD.

Conclusion

The feasibility study conducted by Lehoux et al. demonstrates the promising potential of VR in addiction therapy. By effectively inducing cocaine cravings and providing therapeutic relief through relaxation techniques, VR could become a vital component of modern addiction treatment strategies. As technology advances, the scope for VR in clinical settings continues to expand, offering new hope for individuals battling addiction.

This study marks a pivotal moment in addiction research, showcasing how innovative technologies can be harnessed to improve therapeutic outcomes. The intersection of VR and addiction therapy holds great promise, potentially transforming lives through enhanced treatment methodologies.

For more detailed information, you can access the full study here​​.

The post Virtual Reality Shows Promise in Treating Cocaine Addiction appeared first on Mindheal.

What is Telehealth?

Telehealth, also known as telemedicine, refers to the delivery of healthcare services through digital communication technologies. This innovative approach allows patients to receive medical care, consultations, and support from healthcare providers without needing to visit a clinic or hospital in person. Here are the key components and benefits of telehealth:

Key Components of Telehealth

1. Video Consultations: Patients can have face-to-face appointments with their healthcare providers via video conferencing tools.
2. Remote Monitoring: Devices and apps that monitor patients’ vital signs and health conditions from a distance.
3. Digital Communication: Communication through email, secure messaging, and phone calls between patients and healthcare providers.
4. Mobile Health Apps: Applications that offer health advice, reminders, and support directly to patients’ smartphones.

Understanding the Stigma in OUD Treatment

Opioid use disorder is not just a chronic medical condition; it is also heavily stigmatized. This stigma manifests at multiple levels:

• Individual Level: Patients often internalize negative stereotypes, leading to feelings of shame and reduced self-esteem.
• Public Level: The general public and even healthcare providers can harbor prejudices, resulting in discriminatory behaviors.
• Structural Level: Policies and regulations may implicitly or explicitly discriminate against those seeking treatment.

These layers of stigma can create substantial barriers to accessing and maintaining treatment, further exacerbating the crisis.

The Role of Telehealth in Reducing Stigma

The study explores how telehealth impacts patient experiences of stigma at these different levels. Here are the key findings:

Individual Level: Providing a Safe Space

For many patients, the anonymity and comfort of their own homes made telehealth an attractive option. It reduced the anxiety associated with visiting a clinic and being seen by others:

“To be able to speak to someone in the comfort of my own space… and not have to feel…the excessive anxiety that goes with all of that, was absolutely beneficial for me.”

Public Level: Navigating Privacy and Exposure

Telehealth also helped mitigate public stigma by allowing patients to avoid being seen at OUD treatment centers. However, it introduced new challenges, particularly for those without private spaces at home:

“If I’m in the clinic, then I know that only people that are there to do medical business are there, and aren’t gonna be standing outside the door, listening.”

Structural Level: Enhancing Flexibility and Trust

The flexibility of telehealth often translated to a perception of increased trust and respect from clinicians. Participants felt less judged and more supported in their recovery journey:

“[My telehealth-based clinic] puts a lot more trust in us as people….I’ve never met them in-person; yet they trust me and I trust them…”

Mixed Outcomes and Future Directions

While the benefits of telehealth are clear, the study also highlights potential drawbacks. Some patients felt that the lack of face-to-face interaction could exacerbate feelings of isolation or make it harder to build trust with clinicians. Additionally, clinicians’ comfort and training with telehealth varied, impacting patient experiences.

The research suggests that telehealth can both mitigate and exacerbate stigma, depending on individual circumstances and the specific dynamics of the patient-clinician relationship. Therefore, a one-size-fits-all approach is not sufficient.

Telehealth for Other Addictions

Telehealth’s benefits extend beyond opioid use disorder, showing promise in the treatment of other addictions as well. For patients battling alcohol dependence, methamphetamine addiction, or other substance use disorders, telehealth can provide a similar level of privacy, flexibility, and reduced stigma. This versatile approach allows for continuous support and treatment, even for those in remote or underserved areas, thereby expanding access to critical care and improving overall health outcomes.

Conclusion

Telehealth has emerged as a crucial tool in the fight against the opioid crisis, offering new ways to deliver care and reduce stigma. However, its implementation needs to be carefully managed to address the unique challenges it presents. Policies should support a patient-centered approach, allowing individuals to choose the mode of treatment that best suits their needs while ensuring that clinicians are adequately trained to provide compassionate, stigma-free care through telehealth platforms.

References

• Couch et al., Harm Reduction Journal (2024). “Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.” DOI: 10.1186/s12954-024-01043-5

The post Telehealth: A New Frontier in Stigma Reduction & Addiction Treatment appeared first on Mindheal.

Increasing Access to Essential Treatment

The opioid crisis has led to changes in federal policy aimed at making it easier for doctors to prescribe buprenorphine by removing specialized training requirements and lifting patient limits. Despite these changes, there is still a large gap between the number of people who need buprenorphine and the number who receive it in primary care settings. This study surveyed a representative sample of adults across the country to understand public awareness and attitudes toward receiving opioid addiction treatment from their primary care doctor.

Key Findings

The survey included 1,234 respondents from various backgrounds:

• 56.5% were female, and 43.5% were male
• 11.5% identified as Black, 15.2% as Hispanic or Latino, 68.4% as White, and 4.8% as other or multi-racial

The results showed that a majority of respondents (61.4%) did not know that primary care doctors could prescribe buprenorphine, and 13.3% incorrectly believed that they could not. However, there was strong support for primary care doctors providing opioid addiction treatment, with 53.9% agreeing and 24.9% strongly agreeing that they should.

Comfort with Treatment from Primary Care Doctors

The study also looked at how comfortable people would feel seeking or referring others to their primary care doctor for buprenorphine treatment. Among those who had used opioids:

• 50.6% said they would be very comfortable seeking treatment from their primary care doctor
• 30.7% said they would be somewhat comfortable

Among those who had not used opioids:

• 31.9% said they would be very comfortable referring someone to their primary care doctor for treatment
• 42.0% said they would be somewhat comfortable

Implications and Future Directions

Dr. del Pozo and his team emphasize that increasing public knowledge about the availability of buprenorphine from primary care doctors is essential for expanding access to this life-saving treatment. With around 209,000 primary care doctors across the United States, the healthcare system has a significant opportunity to improve the reach and effectiveness of opioid addiction treatment.

The study highlights the importance of educational campaigns and support for primary care doctors to encourage them to offer buprenorphine treatment. As the fight against the opioid epidemic continues, the role of primary care in providing accessible and comprehensive treatment options will be crucial.

This important research shows the untapped potential of primary care doctors in addressing the opioid crisis with buprenorphine treatment. By raising public awareness and providing support to doctors, the healthcare system can make significant progress in reducing overdose deaths and improving the lives of people with opioid addiction.

For more details, read the full study published in JAMA Network Open here.

The post Few Americans Know PCPs Can Treat Opioid Addiction appeared first on Mindheal.

In diesem Artikel wird ein neuer Ansatz versucht: Jeder Untertitel soll helfen, die Frage, die in der Überschrift gestellt wird, zu beantworten. Erinnere dich also an den Titel dieses Artikels, wenn dir der Untertitel unverständlich oder unpassend erscheint. Es scheint mir etwas Neues zu sein. 

Aber genug der unnötigen Worte, fangen wir an!

Amphetamine, typische Stimulanzien, wirken, indem sie die Konzentration der Neurotransmitter Dopamin und Noradrenalin erhöhen.

Neurotransmitter sind aktive biochemische Substanzen, die zur „Kommunikation“ zwischen den Nervenzellen des Gehirns, zur Übertragung von Impulsen und zur Aufrechterhaltung der Komplexität unseres Nervensystems dienen.

Zur gleichen Gruppe der Neurotransmitter – den Monoaminen – gehören Dopamin und Noradrenalin. Zusammen mit Adrenalin bilden sie außerdem eine Untergruppe, die als Katecholamine bezeichnet wird. Außerdem ist Noradrenalin eine chemische Vorstufe des Adrenalins.

Weil Katecholamine eine Schlüsselrolle bei Aufmerksamkeit, Motivation und Belohnung spielen, können Amphetamine zur Behandlung von Krankheiten wie Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen (ADHS) und Narkolepsie eingesetzt werden.

Durchdringt Nervenzellen

Voraussetzung für die Wirkung von Amphetaminen ist deren Eindringen in die Nervenzelle. Amphetamin gelangt schnell ins Gehirn und infiltriert unsere Nervenzellen über den Blutkreislauf, die Schleimhäute oder direkt.

Amphetamine sind ähnlich aufgebaut wie Katecholamine. Deshalb bindet es Natrium- und Chlorionen. Der Transport in die Nervenzellen erfolgt entweder durch einfache Diffusion oder mit Hilfe des Trägerproteins DAT (auf das wir später noch eingehen werden). Hier beginnt der faszinierendste Teil.

Aufgrund ihrer Komplexität und Vielfalt sind die genauen molekularen Mechanismen, die den Wirkungen von Amphetamin (und vielen anderen Substanzen) zugrunde liegen, noch nicht vollständig erforscht. Mehrere Schlüsselwege spielen jedoch eine Rolle.

Am wichtigsten ist, dass durch Amphetamin die Dopamin- und Noradrenalinspiegel im Gehirn erhöht werden, und zwar auf mehrere Arten gleichzeitig.

Steigert den Monoamin-Spiegel

Durch Amphetamin wird die Ausschüttung von Dopamin und Noradrenalin aus den Nervenzellen (Neuronen) erhöht. In den Nervenzellen werden Neurotransmitter produziert, die jedoch nur dann aktiv werden, wenn sie in den Raum zwischen den Neuronen gelangen, genauer gesagt zwischen die speziellen Vorrichtungen der Neuronen, die chemisch-elektrische Signale übertragen und Synapsen genannt werden. Man bezeichnet den Raum zwischen den Synapsen als intersynaptischen Spalt.

Die Wirkung von Amphetamin stimuliert die Aktivität von Proteinen, die als vesikuläre Monoamin-Transporter (VMATs, insbesondere VMAT2) bezeichnet werden und für den Transport dieser Neurotransmitter zu den Vesikeln verantwortlich sind, in denen sie in den Nervenzellen gespeichert werden.

Erinnern wir uns, dass das Amphetamin aufgrund seiner chemischen Ähnlichkeit mit den Monoaminen in die Synapse eines Neurons eindringt. Für das Amphetamin ist es von Vorteil, wenn es die Spitze der Synapse (präsynaptisches Terminal) erreicht. Es verdrängt andere Monoamine, die mit VMAT2 in Verbindung stehen, was dazu führt, dass Neurotransmitter in den Raum zwischen den Synapsen gepumpt werden – dieser Prozess wird als Retrotransport bezeichnet. Dadurch wird die Menge an Dopamin und Noradrenalin zwischen den Synapsen erhöht.

Außerdem ist Amphetamin ein starker Agonist (aktiviert die Funktion) des Trace-Amin-assoziierten Rezeptors 1 (TAAR1). Dies lässt die Monoamin-Konzentration im synaptischen Spalt ansteigen und verstärkt die Bindung an den postsynaptischen Rezeptor.

Durch die kumulative Wirkung von Amphetamin über VMAT2 und TAAR1 werden Noradrenalin und Dopamin in den Synapsen akkumuliert. Die Signale, die mit diesen Neurotransmittern in Verbindung gebracht werden, beginnen aktiv in die Zentren des Nervensystems einzudringen und die gewünschten Effekte zu erzeugen.

Zusätzlich erhöht Amphetamin die Aktivität der Alpha-2A-adrenergen Rezeptoren im Gehirn, die für die Freisetzung von Noradrenalin verantwortlich sind. Dies führt zu erhöhter Wachsamkeit, Aufmerksamkeit und Energie.

Verringert die Wiederaufnahme von Monoaminen

Doch damit nicht genug: Amphetamine vermindern gleichzeitig die Wiederaufnahme von Dopamin und Noradrenalin. Die Wiederaufnahme ist eine natürliche Reaktion, bei der Neurotransmitter von einer Synapse wieder aufgenommen werden und ihre Signalwirkung auf eine andere Nervenzelle oder Zelle beenden. Zur Regulierung der im Nervensystem ablaufenden Prozesse ist dies notwendig.

Wird die Wiederaufnahme von Signalüberträgern vermindert, reichern sie sich im Spalt zwischen den Synapsen an und erhöhen die Aktivität in den Belohnungs- und Motivationszentren des Gehirns, wie dies bei den Katecholaminen der Fall ist, die den mit Amphetaminen verbundenen „Kick“ oder die Euphorie auslösen.

Amphetamin bindet an Dopamintransporter (Dopamin-aktivierter Transporter, DAT) und möglicherweise auch an Noradrenalin und reduziert oder unterbricht so die Wiederaufnahme von Katecholaminen.

Amphetamin verändert die chemische Struktur des DAT (Phosphorylierung), der in die Nervenzelle aufgenommen wird. Die Anzahl der DATs nimmt ab, was bedeutet, dass auch ihre Funktion abnimmt. Der Transport von Dopamin aus dem synaptischen Spalt zurück in die Synapse ist geringer.

Amphetamin ist bekannt als schwacher Inhibitor der Wiederaufnahme von Dopamin, als moderater Inhibitor der Wiederaufnahme von Noradrenalin und als sehr schwacher Inhibitor der Wiederaufnahme von Serotonin. Dieser Aspekt kann dazu führen, dass Amphetamin eher klassisch stimulierend als euphorisierend wirkt.

Verändert die Rezeptoraktivität und anderes

Die Wirkung von Amphetamin auf das Gehirn wird auch durch die Veränderung der Aktivität bestimmter Rezeptoren beeinflusst. Amphetamin steigert die Aktivität der Dopaminrezeptoren D1 und D2, die an den Belohnungs- und Motivationszentren des Gehirns beteiligt sind, und ermöglicht ihnen so, leichter, schneller und effizienter mit Dopamin zu interagieren und dazu beizutragen, die gewünschten Wirkungen zu erzielen.

Amphetamin hemmt das mitochondriale Enzym Monoaminoxidase (MAO), das für den Abbau überschüssiger Neurotransmitter verantwortlich ist. Durch diese Hemmung wird der Abbau überschüssiger Monoamine verhindert, was zu einem deutlichen Anstieg der Monoaminkonzentration im synaptischen Spalt und damit zu einer Verstärkung der Signalübertragung führt. Da Amphetamin ein schwacher MAO-Hemmer ist, wird die Bedeutung dieses Prozesses oft unterschätzt.

Tritt in verschiedenen Teilen des Gehirns auf

Obwohl wir die Mechanismen untersucht haben, durch die Amphetamine ihre Wirkung entfalten, hat es mehrere Effekte. Wovon hängt es ab? Kurzum: Es ist davon abhängig, welcher Teil des Gehirns von der Wirkung des Amphetamins betroffen ist.

So werden zum Beispiel gesteigerter Antrieb und Euphorie durch eine Erhöhung des Dopaminspiegels im mesolimbischen Pfad hervorgerufen. Dies ist ein Nervenstrang im Gehirn, der eine wichtige Rolle bei Gedächtnis-, Gefühls-, Lern- und neuroendokrinen Regulationsmechanismen spielt und als entscheidend für die Erzeugung von Glücksgefühlen gilt.

Auch die euphorisierende Wirkung des Amphetamins ist auf erhöhte Dopamin- und Noradrenalinspiegel im Striatum zurückzuführen, einer Hirnstruktur, die den Muskeltonus steuert, an Aufmunterungs- und Verstärkungsprozessen beteiligt ist und auch bei der Entstehung impulsiven Verhaltens mitwirkt.

Nicht nur Dopamin und Noradrenalin bestimmen das vollständige Wirkungsprofil von Amphetamin. Weitere Monoamine und andere Wirkstoffe wurden ebenfalls identifiziert: Serotonin, Histamin, CART-Peptide, endogene Opioide, Kortikosteroide und Glutamat. Bekannt ist, dass Amphetamin auch auf all diese Substanzen einwirkt und über sie seine Wirkung entfaltet, aber die genauen Mechanismen und das Gesamtbild der Vorgänge sind noch nicht vollständig verstanden.

The post Wie wirkt Amphetamin? appeared first on Mindheal.